Abstract
Despite major improvements in the surgical management the prognosis for patients bearing malignant gliomas is still dismal. Malignant gliomas are notoriously resistant to treatment and the survival time of patients is between 3-8 years for low-grade and anaplastic gliomas and 6 - 12 month for glioblastoma. Increasing malignancy of gliomas correlates with an increase in cellularity and a poorly organized tumor vasculature leading to insufficient blood supply, hypoxic areas and ultimately to the formation of necrosis, a characteristic of glioblastoma. Hypoxic/necrotic tumors are more resistant to chemotherapy and radiation. Hypoxia induces either directly or indirectly (through the activation of transcription factors) changes in the biology of a tumor and its microenvironment leading to increased aggressiveness and tumor resistance to chemotherapy and radiation. This review is focused on hypoxia-induced molecular changes affecting glioma biology and therapy.
Keywords: Brain tumour, glioma, hypoxia, resistance, chemotherapy, radiotherapy
Current Cancer Drug Targets
Title: Hypoxia Helps Glioma to Fight Therapy
Volume: 9 Issue: 3
Author(s): Verena Amberger-Murphy
Affiliation:
Keywords: Brain tumour, glioma, hypoxia, resistance, chemotherapy, radiotherapy
Abstract: Despite major improvements in the surgical management the prognosis for patients bearing malignant gliomas is still dismal. Malignant gliomas are notoriously resistant to treatment and the survival time of patients is between 3-8 years for low-grade and anaplastic gliomas and 6 - 12 month for glioblastoma. Increasing malignancy of gliomas correlates with an increase in cellularity and a poorly organized tumor vasculature leading to insufficient blood supply, hypoxic areas and ultimately to the formation of necrosis, a characteristic of glioblastoma. Hypoxic/necrotic tumors are more resistant to chemotherapy and radiation. Hypoxia induces either directly or indirectly (through the activation of transcription factors) changes in the biology of a tumor and its microenvironment leading to increased aggressiveness and tumor resistance to chemotherapy and radiation. This review is focused on hypoxia-induced molecular changes affecting glioma biology and therapy.
Export Options
About this article
Cite this article as:
Amberger-Murphy Verena, Hypoxia Helps Glioma to Fight Therapy, Current Cancer Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/156800909788166637
DOI https://dx.doi.org/10.2174/156800909788166637 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment
Current Cancer Drug Targets A Discussion Regarding the Application of the Hertz Contact Theory on Biological Samples in AFM Nanoindentation Experiments
Micro and Nanosystems The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials Flavonoids: The Innocuous Agents Offering Protection against Alzheimer’s Disease Through Modulation of Proinflammatory and Apoptotic Pathways
Current Topics in Medicinal Chemistry Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry VEGF and HIF in Renal Cell Carcinogenesis
Recent Patents on Biomarkers Role of Early Growth Response-1 in the Development of Alcohol-Induced Steatosis
Current Molecular Pharmacology Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Nanoparticulate Formulations for Paclitaxel Delivery Across MDCK Cell Monolayer
Current Pharmaceutical Design Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets